Inclusion Criteria:

          -  Patients with a diagnosis of relapsed or refractory acute myeloid leukemia (AML)
             (including biphenotypic or bilineage leukemia including a myeloid component or
             isolated extramedullary AML); OR

          -  Patients (> 60 year old) with newly diagnosed AML not eligible for intensive
             chemotherapy are also eligible

          -  Age >= 18 years

          -  Subjects must have documented IDH1 or IDH2 gene mutation

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  Adequate renal function including creatinine < 2 unless related to the disease

          -  Direct bilirubin < 2 x upper limit of normal (ULN) unless increase is due to Gilbert's
             disease or leukemic involvement

          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3 x ULN
             unless considered due to leukemic involvement, in which case direct bilirubin or AST
             and/or ALT < 5 x ULN will be considered eligible)

          -  In the absence of rapidly proliferative disease, the interval from prior treatment to
             time of initiation will be at least 7 days for cytotoxic or non-cytotoxic
             (immunotherapy agent(s). Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for
             patients with rapidly proliferative disease is allowed before the start of study
             therapy, as needed, for clinical benefit and after discussion with the principle
             investigator (PI). Concurrent therapy for central nervous system (CNS) prophylaxis or
             continuation of therapy for controlled CNS disease is permitted

          -  Male subjects who are sexually active with a women of childbearing potential (WOCBP)
             and who have not had vasectomies must be willing to use a barrier method of
             contraception and refrain from sperm donation from initial study drug until 90 days
             after last dose of study drug

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia
             (French-American-British [FAB] class M3-AML)

          -  Patients with any concurrent uncontrolled clinically significant medical condition
             including life-threatening severe infection, or psychiatric illness, which could place
             the patient at unacceptable risk of study treatment

          -  Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant
             (patients without active GVHD on chronic suppressive immunosuppression and/or
             phototherapy for chronic skin GVHD are permitted after discussion with the PI)

          -  Patients with any severe gastrointestinal or metabolic condition which could interfere
             with the absorption of oral study medications

          -  Corrected QT (QTc) interval using Fridericia's formula (QTcF) >= 450 msec. Bundle
             branch block and prolonged QTc interval are permitted after discussion with the PI

          -  Known active hepatitis B (HBV) or hepatitis C (HCV) infection or known human
             immunodeficiency virus (HIV) infection

          -  Subject has a white blood cell count > 25 x 10^9/L. (Note: Hydroxyurea is permitted to
             meet this criterion)

          -  Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy
             test, or women of childbearing potential who are not willing to maintain adequate
             contraception

               -  Appropriate highly effective method(s) of contraception include oral or
                  injectable hormonal birth control, intrauterine device (IUD), and double barrier
                  methods (for example a condom in combination with a spermicide)